Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.
Blood. 2024 Apr 21:blood.2024023847. doi: 10.1182/blood.2024023847. Online ahead of print.
Blood. 2024.
PMID: 38643491
Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP.
Martínez-Calle N, et al. Among authors: balotis c.
Br J Haematol. 2019 Mar;184(6):957-968. doi: 10.1111/bjh.15722. Epub 2018 Dec 13.
Br J Haematol. 2019.
PMID: 30548597
Free article.
Item in Clipboard
CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL.
Chen Y, Peubez C, Smith V, Xiong S, Kocsis-Fodor G, Kennedy B, Wagner S, Balotis C, Jayne S, Dyer MJS, Macip S.
Chen Y, et al. Among authors: balotis c.
J Cell Mol Med. 2019 Jan;23(1):340-348. doi: 10.1111/jcmm.13935. Epub 2018 Oct 24.
J Cell Mol Med. 2019.
PMID: 30353642
Free PMC article.
Item in Clipboard
Cite
Cite